Overactive Bladder Update (2024): Expert Guidance for APPs

Overactive Bladder Update (2024): Expert Guidance for APPs CME Available: https://auau.auanet.org/node/42013 After participating in this CME activity, participants will be able to: 1. Adjust methods for diagnosis and treatment of Overactive Bladder (OAB) based on the clinical recommendations from the 2024 AUA/SUFU Guideline. 2. Analyze the indications, mechanisms of action, and dosing regimens for OAB medications. 3. Educate patients on what to expect with OAB treatment and how to report any adverse effects. 4. Utilize appropriate tools and methods to assess the efficacy of OAB treatments in clinical practice. 5. Effectively document the medical necessity for beta3 agonists and other OAB medications to insurance providers. Acknowledgements Support provided by an independent educational grant from: Sumitomo Pharma America, Inc.